Text Size

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne

This study has been completed.
Sponsor:
Information provided by:
PhotoCure
ClinicalTrials.gov Identifier:
NCT00594425
First received: January 3, 2008
Last updated: January 14, 2010
Last verified: January 2010
History of Changes
  Purpose

This multicenter study will be divided into 2 phases. The first phase will be an open label, dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled, parallel-group, dose-response phase. The second phase will only start if the first phase succeeds in establishing well tolerated dose(s). Patients with moderate to severe acne vulgaris in the face will be included.


Condition Intervention Phase
Acne Vulgaris
 Drug: Methyl aminolevulinate (MAL) PDT
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Acne
U.S. FDA Resources

Further study details as provided by PhotoCure:

Primary Outcome Measures:
  • The reduction in facial inflammatory (nodules, papules, and pustules) lesion counts from Baseline [ Time Frame: 3,6,12 and 24 weeks after last treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The reduction in nonfacial inflammatory lesion counts [ Time Frame: 3, 6, 12 and 24 weeks after last treatment ] [ Designated as safety issue: No ]
  • The reduction in total lesion counts for facial and nonfacial assessments [ Time Frame: 3,6,12 and 24 weeks after last treatment ] [ Designated as safety issue: No ]
  • The reduction in noninflammatory (whiteheads and blackheads) lesion counts for facial and nonfacial assessments [ Time Frame: 3,6,12 and 24 weeks after last treatment ] [ Designated as safety issue: No ]
  • Secondary endpoints include erythema score, hyperpigmentation score, hypopigmentation score, other local and nonlocal adverse events, and standard clinical chemistry parameters [ Time Frame: From baseline up to 24 weeks after the last treatment ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 190
Study Start Date: February 2007
Study Completion Date: September 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
PDT using MAL concentration A
 Drug: Methyl aminolevulinate (MAL) PDT
Cream application followed by illumination with red light
Experimental: 2
PDT using MAL concentration B
 Drug: Methyl aminolevulinate (MAL) PDT
Cream application followed by illumination with red light
Placebo Comparator: 3
PDT using Placebo cream
 Drug: Methyl aminolevulinate (MAL) PDT
Cream application followed by illumination with red light

  Eligibility

Ages Eligible for Study:   15 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female and male patients, age 15 to 40 years with moderate to severe facial acne vulgaris (IGA score 3-4).
  2. Patients with skin type I to IV (Fitzpatrick).
  3. Patients with 20 to 100 inflammatory lesions (papules, pustules, and nodules) on the face excluding lesions on the nose and in the peri-ocular area.
  4. Patients with up to 200 noninflammatory lesions (open and closed comedones) on the face.
  5. Patients with no more than 2 nodular lesions on the face.
  6. Patients who are surgically sterile, postmenopausal, abstinent, or willing to use an adequate means of contraception including birth control pills, or barrier methods and spermicide for at least 14 days prior to Day 0. Patients using birth control pills must have used the same product and dose for at least 6 months and must agree to stay with the same product and dose for an additional 6 months.
  7. Patients must be willing and capable of following study instructions to the extent and degree required by the protocol.
  8. Patients must sign the approved informed consent form prior to any study procedures.
  9. Patients must be willing to be photographed. Patients must be willing to sign a photography consent form.

Exclusion Criteria:

  1. Known allergy to MAL, to a similar PDT compound, or to excipients of the cream.
  2. Participation in other clinical studies either concurrently or within the last 30 days.
  3. Patients who have a condition or who are in a situation, which, in the investigator's opinion, may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the study.
  4. Clinically significant sensitivity to visible light, or has porphyria or porphyrin sensitivity.
  5. Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within the last 30 days.
  6. Patients with a washout period for topical treatments for their acne of less than 14 days. Medicated cleansers may be used during the washout period and stopped before the treatment.
  7. Patients with a washout period for oral antibiotics for treatment of their acne of less than 1 month.
  8. Patients with a washout period for oral isotretinoin of less than 6 months.
  9. Patients with a beard or other facial hair that might interfere with study assessments.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00594425

Locations
United States, Virginia
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
PhotoCure
Investigators
Principal Investigator: David Pariser, MD AAD
  More Information

No publications provided

Responsible Party: Sylvia Vetrhus, Clinical Trial Manager, Photocure
ClinicalTrials.gov Identifier: NCT00594425     History of Changes
Other Study ID Numbers: PC TA202B/06
Study First Received: January 3, 2008
Last Updated: January 14, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Facial Dermatoses
Sebaceous Gland Diseases
Aminolevulinic Acid
Methyl 5-aminolevulinate
 Photosensitizing Agents
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013